CoChat

mTORC1 activity regulates post-translational modifications of glycine decarboxylase to modulate glycine metabolism and tumorigenesis

Open access
Liu, Rui, Zeng, Lin-Wen, Gong, Rong, Yuan, Fanen, Shu, Hong-Bing, Li, Shu · 2021 · Nature Communications

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Abstract

Glycine decarboxylase (GLDC) is a key enzyme of glycine cleavage system that converts glycine into one-carbon units. GLDC is commonly up-regulated and plays important roles in many human cancers. Whether and how GLDC is regulated by post-translational modifications is unknown. Here we report that mechanistic target of rapamycin complex 1 (mTORC1) signal inhibits GLDC acetylation at lysine (K) 514 by inducing transcription of the deacetylase sirtuin 3 (SIRT3). Upon inhibition of mTORC1, the acetyltransferase acetyl-CoA acetyltransferase 1 (ACAT1) catalyzes GLDC K514 acetylation. This acetylation of GLDC impairs its enzymatic activity. In addition, this acetylation of GLDC primes for its K33-linked polyubiquitination at K544 by the ubiquitin ligase NF-X1, leading to its degradation by the proteasomal pathway. Finally, we find that GLDC K514 acetylation inhibits glycine catabolism, pyrimidines synthesis and glioma tumorigenesis. Our finding reveals critical roles of post-translational modifications of GLDC in regulation of its enzymatic activity, glycine metabolism and tumorigenesis, and provides potential targets for therapeutics of cancers such as glioma.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41467-021-24321-3

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Inhibition of mTORC1 suppresses GLDC activity by promoting its acetylation at K514. a Rapamycin inhibits GLDC activity. U251 cells stably expressing Flag-GLDC were treated with Rapamycin (50 nM) for the indicated times. Flag-GLDC protein was purified by anti-Flag beads; equal amounts of each purified proteins (2.5 μg) were used for GLDC activity assay. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. b Rapamycin promotes endogenous GLDC acetylation. U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c Effects of RPTOR deficiency on GLDC acetylation. Control or RPTOR-deficient HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. d Effects of Rapamycin on acetylation of wild-type GLDC and its mutants. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. e, f Rapamycin promotes GLDC K514 acetylation. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies (e). The control or GLDC-deficient U251 cells were treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies (f). g Effects of GLDC mutations on its activity. HEK293 cells were transfected with the indicated plasmids for 24 h and treated with DMSO or Rapamycin (50 nM) for 12 h. The Flag-tagged GLDC and its mutants were purified by anti-Flag beads and equal amounts of each purified proteins (2.5 μg) were used for GLDC activity assay. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file.
Fig. 1 Inhibition of mTORC1 suppresses GLDC activity by promoting its acetylation at K514. a Rapamycin inhibits GLDC activity. U251 cells stably expressing Flag-GLDC were treated with Rapamycin (50 nM) for the indicated times. Flag-GLDC protein was purified by anti-Flag beads; equal amounts of each purified proteins (2.5 μg) were used for GLDC activity assay. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. b Rapamycin promotes endogenous GLDC acetylation. U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c Effects of RPTOR deficiency on GLDC acetylation. Control or RPTOR-deficient HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. d Effects of Rapamycin on acetylation of wild-type GLDC and its mutants. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. e, f Rapamycin promotes GLDC K514 acetylation. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies (e). The control or GLDC-deficient U251 cells were treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies (f). g Effects of GLDC mutations on its activity. HEK293 cells were transfected with the indicated plasmids for 24 h and treated with DMSO or Rapamycin (50 nM) for 12 h. The Flag-tagged GLDC and its mutants were purified by anti-Flag beads and equal amounts of each purified proteins (2.5 μg) were used for GLDC activity assay. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 2 ACAT1 mediates GLDC K514 acetylation. a ACAT1 is associated with GLDC. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. b ACAT1 mediates GLDC acetylation at K514. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c Effects of ACAT1 on acetylation of wild-type GLDC or GLDCK514R in vitro. GST-GLDC was purified from E. coli. Flag-ACAT1 was purified from HEK293 cells. The purified proteins were incubated for acetylation assays, followed by immunoblotting analysis with the indicated antibodies. d ACAT1 deficiency inhibits Rapamycin-induced GLDC acetylation. The control or ACAT1-deficient U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. e Effects of ACAT1 on GLDC activity. HEK293 (left histograph) or ACAT1-deficient HEK293 (right histograph) cells were transfected with the indicated plasmids for 24 h before purification of Flag-GLDC, Flag-GLDCK514R, and Flag-GLDCK514Q. Equal amounts of each purified proteins (2.5 μg) were used for GLDC activity assay. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file.
Fig. 2 ACAT1 mediates GLDC K514 acetylation. a ACAT1 is associated with GLDC. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. b ACAT1 mediates GLDC acetylation at K514. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c Effects of ACAT1 on acetylation of wild-type GLDC or GLDCK514R in vitro. GST-GLDC was purified from E. coli. Flag-ACAT1 was purified from HEK293 cells. The purified proteins were incubated for acetylation assays, followed by immunoblotting analysis with the indicated antibodies. d ACAT1 deficiency inhibits Rapamycin-induced GLDC acetylation. The control or ACAT1-deficient U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. e Effects of ACAT1 on GLDC activity. HEK293 (left histograph) or ACAT1-deficient HEK293 (right histograph) cells were transfected with the indicated plasmids for 24 h before purification of Flag-GLDC, Flag-GLDCK514R, and Flag-GLDCK514Q. Equal amounts of each purified proteins (2.5 μg) were used for GLDC activity assay. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 3 SIRT3 deacetylases GLDC at K514. a NAM promotes GLDC K514 acetylation. U251 or U87 cells were untreated or treated with NAM (80 μM) or TSA (100 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. b SIRT3 mediates GLDC deacetylation. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c SIRT3 deacetylates GLDC at K514. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. d SIRT3 mediates GLDC K514 deacetylation in vitro. The indicated recombinant proteins were incubated for deacetylation assays before immunoblotting analysis with the indicated antibodies. e SIRT3 deficiency promotes GLDC K514 acetylation. The control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. f Rapamycin fails to further increase GLDC K514 acetylation in SIRT3-deficient cells. The control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 12 h and then untreated or treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. g Effects of SIRT3 or SIRT3H248Y on GLDC activity. HEK293 (left histograph) or SIRT3-deficient HEK293 (right histograph) cells were transfected with the indicated plasmids for 24 h before purification of Flag-GLDC, Flag-GLDCK514Q, and Flag-GLDCK514R. Equal amounts of each purified proteins (2.5 μg) were used for GLDC activity assay. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file.
Fig. 3 SIRT3 deacetylases GLDC at K514. a NAM promotes GLDC K514 acetylation. U251 or U87 cells were untreated or treated with NAM (80 μM) or TSA (100 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. b SIRT3 mediates GLDC deacetylation. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c SIRT3 deacetylates GLDC at K514. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. d SIRT3 mediates GLDC K514 deacetylation in vitro. The indicated recombinant proteins were incubated for deacetylation assays before immunoblotting analysis with the indicated antibodies. e SIRT3 deficiency promotes GLDC K514 acetylation. The control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. f Rapamycin fails to further increase GLDC K514 acetylation in SIRT3-deficient cells. The control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 12 h and then untreated or treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. g Effects of SIRT3 or SIRT3H248Y on GLDC activity. HEK293 (left histograph) or SIRT3-deficient HEK293 (right histograph) cells were transfected with the indicated plasmids for 24 h before purification of Flag-GLDC, Flag-GLDCK514Q, and Flag-GLDCK514R. Equal amounts of each purified proteins (2.5 μg) were used for GLDC activity assay. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 4 mTORC1 signal upregulates SIRT3. a Effects of ACAT1 on GLDC acetylation. Recombinant GST-GLDC was purified from E. coli. Flag-ACAT1 was immunoprecipitated from HEK293 cells after treatment with Rapamycin (50 nM) for the indicated times. The purified proteins were incubated for acetylation assay, followed by immunoblotting analysis with the indicated antibodies. b Effects of Rapamycin on GLDC and SIRT3 interaction. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c Rapamycin downregulates SIRT3 levels. U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before immunoblotting analysis with the indicated antibodies. The GLDC or SIRT3 band intensities relative to the corresponding β-actin bands were shown in the histograph. d Effects of Rapamycin treatment on SIRT3 degradation. U251 cells were pretreated with DMSO or Rapamycin (50 nM) for 6 h, then treated with CHX (0.1 mM) for the indicated times before immunoblots with the indicated antibodies. The SIRT3 band intensities relative to the corresponding β-actin bands are shown in the histograph. e Rapamycin inhibits SIRT3 mRNA levels. U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before qPCR analysis of mRNA levels of the indicated genes. Graph shows mean ± SEM, n = 3 independent samples from one representative experiment. Data were analyzed using two-way ANOVA with GraphPad Prism 7. f PGC1α deficiency inhibits SIRT3 mRNA levels. Control and PGC1α-deficient U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for 6 h before qPCR analysis of mRNA levels of the indicated genes. Graph shows mean ± SEM, n = 3 independent samples from one representative experiment. Data were analyzed using two-way ANOVA with GraphPad Prism 7. g PGC1α deficiency increases acetylation of GLDC at K514. Control and PGC1α-deficient U251 or U87 cells were lysed. Co-immunoprecipitation and immunoblotting analysis were performed with the indicated antibodies. Source data are provided as a Source data file.
Fig. 4 mTORC1 signal upregulates SIRT3. a Effects of ACAT1 on GLDC acetylation. Recombinant GST-GLDC was purified from E. coli. Flag-ACAT1 was immunoprecipitated from HEK293 cells after treatment with Rapamycin (50 nM) for the indicated times. The purified proteins were incubated for acetylation assay, followed by immunoblotting analysis with the indicated antibodies. b Effects of Rapamycin on GLDC and SIRT3 interaction. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c Rapamycin downregulates SIRT3 levels. U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before immunoblotting analysis with the indicated antibodies. The GLDC or SIRT3 band intensities relative to the corresponding β-actin bands were shown in the histograph. d Effects of Rapamycin treatment on SIRT3 degradation. U251 cells were pretreated with DMSO or Rapamycin (50 nM) for 6 h, then treated with CHX (0.1 mM) for the indicated times before immunoblots with the indicated antibodies. The SIRT3 band intensities relative to the corresponding β-actin bands are shown in the histograph. e Rapamycin inhibits SIRT3 mRNA levels. U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before qPCR analysis of mRNA levels of the indicated genes. Graph shows mean ± SEM, n = 3 independent samples from one representative experiment. Data were analyzed using two-way ANOVA with GraphPad Prism 7. f PGC1α deficiency inhibits SIRT3 mRNA levels. Control and PGC1α-deficient U251 or U87 cells were treated with DMSO or Rapamycin (50 nM) for 6 h before qPCR analysis of mRNA levels of the indicated genes. Graph shows mean ± SEM, n = 3 independent samples from one representative experiment. Data were analyzed using two-way ANOVA with GraphPad Prism 7. g PGC1α deficiency increases acetylation of GLDC at K514. Control and PGC1α-deficient U251 or U87 cells were lysed. Co-immunoprecipitation and immunoblotting analysis were performed with the indicated antibodies. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 5 GLDC K514 acetylation promotes its K33-linked polyubiquitination and proteasomal degradation. a SIRT3 deficiency downregulates GLDC levels. The control and SIRT3-deficient U251 or U87 cells were reconstituted with wild-type SIRT3 or SIRT3H248Y and then untreated or treated with DMSO or Rapamycin (50 nM) for 12 h before immunoblotting analysis with the indicated antibodies. b Half-lives of wild-type GLDC and GLDCK514Q. HEK293 cells transfected with wild-type GLDC or GLDCK514Q were untreated or treated with CHX (0.1 mM) for the indicated times before immunoblotting analysis. The wild-type GLDC or GLDCK514Q band intensities relative to the corresponding HA-β-actin bands are shown in the histograph. c MG132 inhibits GLDC degradation. U251 cells were treated with CHX (0.1 mM), MG132 (100 μM), NH4Cl (25 mM), or 3-MA (500 ng/ml) as indicated for 4 h before immunoblotting analysis with the indicated antibodies. d MG132 inhibits the degradation of GLDCK514Q. HEK293 cells were transfected with wild-type GLDC or GLDCK514Q for 20 h. The cells were then treated with MG132 (100 μM), NH4Cl (25 mM), or 3-MA (500 ng/ml) for 6 h before immunoblotting analysis with the indicated antibodies. e MG132 inhibits Rapamycin-induced degradation of GLDC. U251 cells were treated with DMSO or Rapamycin (50 nM) for 10 h and then treated with MG132 (100 μM) for 6 h before immunoblotting analysis with the indicated antibodies. f Rapamycin promotes GLDC polyubiquitination. Control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. g SIRT3 deficiency promotes K33-linked polyubiquitination of GLDC. Control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. h Effects of K514 mutation of GLDC on its K33-linked polyubiquitination. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. i Overexpression of SIRT3 abolished rapamycin-induced K33-linked polyubiquitination of GLDC. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. Source data are provided as a Source data file.
Fig. 5 GLDC K514 acetylation promotes its K33-linked polyubiquitination and proteasomal degradation. a SIRT3 deficiency downregulates GLDC levels. The control and SIRT3-deficient U251 or U87 cells were reconstituted with wild-type SIRT3 or SIRT3H248Y and then untreated or treated with DMSO or Rapamycin (50 nM) for 12 h before immunoblotting analysis with the indicated antibodies. b Half-lives of wild-type GLDC and GLDCK514Q. HEK293 cells transfected with wild-type GLDC or GLDCK514Q were untreated or treated with CHX (0.1 mM) for the indicated times before immunoblotting analysis. The wild-type GLDC or GLDCK514Q band intensities relative to the corresponding HA-β-actin bands are shown in the histograph. c MG132 inhibits GLDC degradation. U251 cells were treated with CHX (0.1 mM), MG132 (100 μM), NH4Cl (25 mM), or 3-MA (500 ng/ml) as indicated for 4 h before immunoblotting analysis with the indicated antibodies. d MG132 inhibits the degradation of GLDCK514Q. HEK293 cells were transfected with wild-type GLDC or GLDCK514Q for 20 h. The cells were then treated with MG132 (100 μM), NH4Cl (25 mM), or 3-MA (500 ng/ml) for 6 h before immunoblotting analysis with the indicated antibodies. e MG132 inhibits Rapamycin-induced degradation of GLDC. U251 cells were treated with DMSO or Rapamycin (50 nM) for 10 h and then treated with MG132 (100 μM) for 6 h before immunoblotting analysis with the indicated antibodies. f Rapamycin promotes GLDC polyubiquitination. Control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. g SIRT3 deficiency promotes K33-linked polyubiquitination of GLDC. Control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. h Effects of K514 mutation of GLDC on its K33-linked polyubiquitination. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for 12 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. i Overexpression of SIRT3 abolished rapamycin-induced K33-linked polyubiquitination of GLDC. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 6 NF-X1 mediates K33-linked polyubiquitination of GLDC. a Association of GLDC with NF-X1. U251 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. b GLDCK514Q interacts with NF-X1 better than wild-type GLDC. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c NF-X1 promotes K33-linked polyubiquitination of GLDC. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. d NF-X1 deficiency impairs Rapamycin-induced K33-linked polyubiquitination of GLDC. Control or NF-X1-deficient HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. e NF-X1 increases K33-linked polyubiquitination of wild-type GLDC and GLDCK539R but not GLDCK544R. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. f SIRT3 deficiency increases K33-linked polyubiquitination of wild-type GLDC and GLDCK539R but not GLDCK544R. Control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. g Rapamycin induces downregulation of wild-type GLDC but not GLDCK544R. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for 16 h before immunoblotting analysis with the indicated antibodies. h NF-X1 deficiency inhibits Rapamycin-induced degradation of GLDC. Control or NF-X1-deficient U251 cells were untreated or treated with Rapamycin (50 nM) for the indicated times before immunoblotting analysis. The GLDC band intensities relative to the corresponding β-actin bands are shown in the histograph. Source data are provided as a Source data file.
Fig. 6 NF-X1 mediates K33-linked polyubiquitination of GLDC. a Association of GLDC with NF-X1. U251 cells were treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. b GLDCK514Q interacts with NF-X1 better than wild-type GLDC. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. c NF-X1 promotes K33-linked polyubiquitination of GLDC. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. d NF-X1 deficiency impairs Rapamycin-induced K33-linked polyubiquitination of GLDC. Control or NF-X1-deficient HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for the indicated times before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. e NF-X1 increases K33-linked polyubiquitination of wild-type GLDC and GLDCK539R but not GLDCK544R. HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. f SIRT3 deficiency increases K33-linked polyubiquitination of wild-type GLDC and GLDCK539R but not GLDCK544R. Control or SIRT3-deficient HEK293 cells were transfected with the indicated plasmids for 24 h before co-immunoprecipitation and immunoblotting analysis with the indicated antibodies. g Rapamycin induces downregulation of wild-type GLDC but not GLDCK544R. HEK293 cells were transfected with the indicated plasmids for 12 h and then treated with DMSO or Rapamycin (50 nM) for 16 h before immunoblotting analysis with the indicated antibodies. h NF-X1 deficiency inhibits Rapamycin-induced degradation of GLDC. Control or NF-X1-deficient U251 cells were untreated or treated with Rapamycin (50 nM) for the indicated times before immunoblotting analysis. The GLDC band intensities relative to the corresponding β-actin bands are shown in the histograph. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 7 Inhibition of mTORC1 promotes GLDC cytoplasm translocation. a Rapamycin promotes GLDC cytoplasm translocation. Control or NF-X1-deficient U251 (left) or U87 (right) cells were untreated or treated with Rapamycin (50 nM) for the indicated times before subcellular fractionation experiments. Subcellular fractions were co-immunoprecipitated and analyzed by immunoblotting with the indicated antibodies. The band intensities of mitochondrial or cytosolic GLDC relative to the total levels are shown in the lower histographs. Mito mitochondria, Cyto cytosol. Graph shows mean ± SEM, n = 3 independent experiments. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file. b The subcellular localization of GLDC. U251 cells were treated with DMSO or Rapamycin (50 nM) for 12 h, then further treated with Mito-TrackerTM Red CMXRos (red) for 30 min. The cells were fixed and stained with anti-GLDC (green) and DAPI (blue) before confocal microscopy. Scale bar, 20 μm.
Fig. 7 Inhibition of mTORC1 promotes GLDC cytoplasm translocation. a Rapamycin promotes GLDC cytoplasm translocation. Control or NF-X1-deficient U251 (left) or U87 (right) cells were untreated or treated with Rapamycin (50 nM) for the indicated times before subcellular fractionation experiments. Subcellular fractions were co-immunoprecipitated and analyzed by immunoblotting with the indicated antibodies. The band intensities of mitochondrial or cytosolic GLDC relative to the total levels are shown in the lower histographs. Mito mitochondria, Cyto cytosol. Graph shows mean ± SEM, n = 3 independent experiments. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file. b The subcellular localization of GLDC. U251 cells were treated with DMSO or Rapamycin (50 nM) for 12 h, then further treated with Mito-TrackerTM Red CMXRos (red) for 30 min. The cells were fixed and stained with anti-GLDC (green) and DAPI (blue) before confocal microscopy. Scale bar, 20 μm.CC BY · PubMed Central
Fig. 8 GLDC K514 acetylation inhibits glycine catabolism and pyrimidine synthesis. a–c Reconstitution of GLDC-deficient U251 cells with wild-type GLDC or GLDCK514Q. Lysates of the indicated cells were analyzed by immunoblots with the indicated antibodies (a). The control and reconstituted cells were analyzed for levels of glycine and glycine-related metabolites (b) and pyrimidines (c) by LC-HRMS. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. d Effects of ACAT1, SIRT3, or NF-X1 deficiency on cellular levels of glycine, glycine-related metabolites, and pyrimidines. Levels of glycine and its metabolites in the indicated cells were measured by LC-HRMS. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file.
Fig. 8 GLDC K514 acetylation inhibits glycine catabolism and pyrimidine synthesis. a–c Reconstitution of GLDC-deficient U251 cells with wild-type GLDC or GLDCK514Q. Lysates of the indicated cells were analyzed by immunoblots with the indicated antibodies (a). The control and reconstituted cells were analyzed for levels of glycine and glycine-related metabolites (b) and pyrimidines (c) by LC-HRMS. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. d Effects of ACAT1, SIRT3, or NF-X1 deficiency on cellular levels of glycine, glycine-related metabolites, and pyrimidines. Levels of glycine and its metabolites in the indicated cells were measured by LC-HRMS. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. Source data are provided as a Source data file.CC BY · PubMed Central
Fig. 9 GLDC K514 acetylation suppresses tumorigenesis. a GLDC deficiency suppresses cell proliferation. Control and GLDC-deficient U251 or U87 cells reconstituted with wild-type GLDC or GLDCK514Q were subjected to proliferation analysis. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. b Relative levels of the indicated proteins or their modifications. Relative levels of the indicated proteins or their modifications in Fig. S7 were plotted based on densitometry quantitation of the indicated proteins or their modifications with the ImageJ software. The GLDC, ACAT1, SIRT3, or NF-X1 band intensities relative to the corresponding β-actin bands, the Ac-K514-GLDC band intensities relative to the corresponding GLDC bands, and the p-P70 S6K band intensities relative to the corresponding P70 S6K bands are shown in the histograph. Graph shows mean ± SEM, n = 18 biologically independent samples. The line in the box is the median value. The bottom and top of the box are the 25th and 75th percentiles of the samples. The bottom and top of the whiskers are the minimum and maximum values of the samples. Data were analyzed using two-way ANOVA with GraphPad Prism 7. c–e Analysis of correlation of GLDC K514 acetylation with GLDC, SIRT3, and ACAT1 (c), GLDC with ACAT1, NF-X1, and SIRT3 (d), and p-p70 S6K with GLDC, SIRT3, and GLDC K514 acetylation (e) in GBM samples. Relative levels of the indicated proteins or their modifications are based on results from Fig. 9b and Fig. S7. Graph shows scatter plot, n = 36 biologically independent samples. Data were analyzed using two-tailed unpaired t test with GraphPad Prism 7. f A working model on regulation of GLDC activity by coordinated acetylation and polyubiquitination. See the text for details. Source data are provided as a Source data file.
Fig. 9 GLDC K514 acetylation suppresses tumorigenesis. a GLDC deficiency suppresses cell proliferation. Control and GLDC-deficient U251 or U87 cells reconstituted with wild-type GLDC or GLDCK514Q were subjected to proliferation analysis. Graph shows mean ± SEM, n = 3 technical repeats. Data were analyzed using two-way ANOVA with GraphPad Prism 7. b Relative levels of the indicated proteins or their modifications. Relative levels of the indicated proteins or their modifications in Fig. S7 were plotted based on densitometry quantitation of the indicated proteins or their modifications with the ImageJ software. The GLDC, ACAT1, SIRT3, or NF-X1 band intensities relative to the corresponding β-actin bands, the Ac-K514-GLDC band intensities relative to the corresponding GLDC bands, and the p-P70 S6K band intensities relative to the corresponding P70 S6K bands are shown in the histograph. Graph shows mean ± SEM, n = 18 biologically independent samples. The line in the box is the median value. The bottom and top of the box are the 25th and 75th percentiles of the samples. The bottom and top of the whiskers are the minimum and maximum values of the samples. Data were analyzed using two-way ANOVA with GraphPad Prism 7. c–e Analysis of correlation of GLDC K514 acetylation with GLDC, SIRT3, and ACAT1 (c), GLDC with ACAT1, NF-X1, and SIRT3 (d), and p-p70 S6K with GLDC, SIRT3, and GLDC K514 acetylation (e) in GBM samples. Relative levels of the indicated proteins or their modifications are based on results from Fig. 9b and Fig. S7. Graph shows scatter plot, n = 36 biologically independent samples. Data were analyzed using two-tailed unpaired t test with GraphPad Prism 7. f A working model on regulation of GLDC activity by coordinated acetylation and polyubiquitination. See the text for details. Source data are provided as a Source data file.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 32 references

Cited by

See all 68

Metadata

Authors
Liu, R., Zeng, L.-W., Gong, R., Yuan, F., Shu, H.-B., & Li, S.
Affiliations
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Wuhan University (CN)
  • Renmin Hospital of Wuhan University (CN)
Corresponding author
Li, Shu
Venue
Nature Communications
Published
2021-07-09
Volume
12
Issue
1
Pages
4227-4227
ISSN
2041-1723 (ISSN-L)
OpenAlex
W3180569188
Cited by
67
References
32
Citations by year
2026: 11 · 2025: 21 · 2024: 16 · 2023: 10 · 2022: 9
FWCI
2.75
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Communications (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • RePEc: Research Papers in Economics (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • National Natural Science Foundation of China
  • the State Key R&D Program of China
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA modifications and cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Keywords
glycine decarboxylase, mTORC1, post-translational modification, lysine acetylation, SIRT3, ACAT1, polyubiquitination, proteasomal degradation, glycine cleavage system, glycine metabolism, pyrimidine synthesis, glioma, carcinogenesis, one-carbon metabolism
MeSH terms
Mechanistic Target of Rapamycin Complex 1, Acetyl-CoA C-Acetyltransferase, Acetylation, Animals, Glioma, Glycine, Humans, Male, Protein Processing, Post-Translational, Pyrimidines, Repressor Proteins, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Xenograft Model Antitumor Assays, Cell Line, Tumor, Proteasome Endopeptidase Complex, Glycine Dehydrogenase (Decarboxylating), Mice, Ubiquitination, Sirtuin 3, HEK293 Cells, Proteolysis, Carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mTORC1 activity regulates post-translational modifications of glycine decarboxylase to modulate glycine metabolism and tumorigenesis. https://app.cochat.ai/papers/10.1038/s41467-021-24321-3
The paper
Liu, R., Zeng, L.-W., Gong, R., Yuan, F., Shu, H.-B., & Li, S. (2021). mTORC1 activity regulates post-translational modifications of glycine decarboxylase to modulate glycine metabolism and tumorigenesis. Nature Communications. https://doi.org/10.1038/s41467-021-24321-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.